These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 22412042)

  • 1. HER2-negative (1+) breast cancer with unfavorable prognostic features: to FISH or not to FISH?
    Iorfida M; Dellapasqua S; Bagnardi V; Cardillo A; Rotmensz N; Mastropasqua MG; Bottiglieri L; Goldhirsch A; Viale G; Colleoni M
    Ann Oncol; 2012 May; 23(5):1371-1372. PubMed ID: 22412042
    [No Abstract]   [Full Text] [Related]  

  • 2. Counterpoint: Both immunohistochemistry and fluorescence in situ hybridization play important roles for HER2 evaluation.
    Bloom KJ; Cote RJ
    Clin Chem; 2011 Jul; 57(7):983-5. PubMed ID: 21558454
    [No Abstract]   [Full Text] [Related]  

  • 3. The identification of a small but significant subset of patients still targetable with anti-HER2 inhibitors when affected by triple negative breast carcinoma.
    Brunello E; Bogina G; Bria E; Vergine M; Zamboni G; Pedron S; Daniele I; Furlanetto J; Carbognin L; Marconi M; Manfrin E; Ibrahim M; Miller K; Tortora G; Molino A; Jasani B; Beccari S; Bonetti F; Chilosi M; Martignoni G; Brunelli M
    J Cancer Res Clin Oncol; 2013 Sep; 139(9):1563-8. PubMed ID: 23892410
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantitative determination of HER2 expression by confocal microscopy assay in CTCs of breast cancer.
    Cao S; Li Y; Li J; Li CF; Zhang W; Yang ZQ; Meng SD
    Oncol Rep; 2010 Feb; 23(2):423-8. PubMed ID: 20043103
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantitative HER2 protein levels predict outcome in fluorescence in situ hybridization-positive patients with metastatic breast cancer treated with trastuzumab.
    Lipton A; Köstler WJ; Leitzel K; Ali SM; Sperinde J; Weidler J; Paquet A; Sherwood T; Huang W; Bates M;
    Cancer; 2010 Nov; 116(22):5168-78. PubMed ID: 20661914
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fluorescence in situ hybridization for HER-2/neu amplification of breast carcinoma in archival fine needle aspiration biopsy specimens.
    Gu M; Ghafari S; Zhao M
    Acta Cytol; 2005; 49(5):471-6. PubMed ID: 16334021
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HER2 evaluation and its impact on breast cancer treatment decisions.
    Goddard KA; Weinmann S; Richert-Boe K; Chen C; Bulkley J; Wax C
    Public Health Genomics; 2012; 15(1):1-10. PubMed ID: 21540562
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneity.
    Hanna WM; Rüschoff J; Bilous M; Coudry RA; Dowsett M; Osamura RY; Penault-Llorca F; van de Vijver M; Viale G
    Mod Pathol; 2014 Jan; 27(1):4-18. PubMed ID: 23807776
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Laboratory testing for HER2/neu in breast carcinoma: an evolving strategy to predict response to targeted therapy.
    Diaz NM
    Cancer Control; 2001; 8(5):415-8. PubMed ID: 11579337
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intrinsic and acquired resistance to HER2-targeted therapies in HER2 gene-amplified breast cancer: mechanisms and clinical implications.
    Rexer BN; Arteaga CL
    Crit Rev Oncog; 2012; 17(1):1-16. PubMed ID: 22471661
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation of human epidermal growth factor receptor 2 expression with clinicopathological characteristics and prognosis in gastric cancer.
    He C; Bian XY; Ni XZ; Shen DP; Shen YY; Liu H; Shen ZY; Liu Q
    World J Gastroenterol; 2013; 19(14):2171-8. PubMed ID: 23599643
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Status of HER2 amplification, polysomy 17 and histopathological features of 425 Pakistani breast cancer patients.
    Moatter T; Aban M; Iqbal W; Azam I; Pervaiz A; Siddiqui F; Murad F; Pervez S
    Asian Pac J Cancer Prev; 2011; 12(11):3069-73. PubMed ID: 22393991
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HER2 assessment by silver in situ hybridization: where are we now?
    Sanguedolce F; Bufo P
    Expert Rev Mol Diagn; 2015 Mar; 15(3):385-98. PubMed ID: 25578771
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Recent advances in targeted therapies in the treatment of HER2-positive metastatic breast cancer].
    Ismaili N; Belbaraka R; Elomrani A; Khouchani M; Tahri A
    Presse Med; 2013 Nov; 42(11):1461-8. PubMed ID: 23721860
    [TBL] [Abstract][Full Text] [Related]  

  • 15. T-DM1, a novel antibody-drug conjugate, is highly effective against primary HER2 overexpressing uterine serous carcinoma in vitro and in vivo.
    English DP; Bellone S; Schwab CL; Bortolomai I; Bonazzoli E; Cocco E; Buza N; Hui P; Lopez S; Ratner E; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Santin AD
    Cancer Med; 2014 Oct; 3(5):1256-65. PubMed ID: 24890382
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of Estrogen Receptor and Human Epidermal Growth Factor Receptor-2 Levels on the Efficacy of Trastuzumab: A Secondary Analysis of the HERA Trial.
    Loi S; Dafni U; Karlis D; Polydoropoulou V; Young BM; Willis S; Long B; de Azambuja E; Sotiriou C; Viale G; Rüschoff J; Piccart MJ; Dowsett M; Michiels S; Leyland-Jones B
    JAMA Oncol; 2016 Aug; 2(8):1040-7. PubMed ID: 27100299
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinicopathologic characteristics of HER2 FISH-ambiguous breast cancer at a single institution.
    Clay MR; Iberri DJ; Bangs CD; Cherry A; Jensen KC
    Am J Surg Pathol; 2013 Jan; 37(1):120-7. PubMed ID: 23108020
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Confirmation of a low HER2 positivity rate of breast carcinomas - limitations of immunohistochemistry and in situ hybridization.
    Vogel UF
    Diagn Pathol; 2010 Jul; 5():50. PubMed ID: 20670419
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association between gain-of-function mutations in PIK3CA and resistance to HER2-targeted agents in HER2-amplified breast cancer cell lines.
    Kataoka Y; Mukohara T; Shimada H; Saijo N; Hirai M; Minami H
    Ann Oncol; 2010 Feb; 21(2):255-262. PubMed ID: 19633047
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Point: Fluorescence in situ hybridization is the preferred approach over immunohistochemistry for determining HER2 status.
    Ross JS
    Clin Chem; 2011 Jul; 57(7):980-2. PubMed ID: 21558455
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.